The researchers discovered that there is no difference between the treatment groups with respect to procedures of atheroma burden at baseline. The principal efficacy measure, PAV, decreased by 0.33 % in the aliskiren group and increased by 0.11 % in the placebo group . There have been no significant differences in the proportion of participants who demonstrated regression of PAV and total atheroma volume in the aliskiren and placebo groupings, respectively. A greater number of discontinuations of participation due to adverse events were observed in the aliskiren group compared with the placebo group . ‘These findings do not support the usage of aliskiren for regression or avoidance of progression of coronary atherosclerosis,’ the authors conclude..But he concludes that the mistake stemmed much less from the EHR itself than from its results on our collective psychology. There’s the critical care doctor who, struggling to identify new info in daily notes, has started printing them out and holding two superimposed pages up to the light to find what’s changed. I could be youthful. Physicians retiring early. Small methods bankrupted by up-front expenses or locked into ineffective systems by the prohibitive price of switching.